Claims

1. A tablet comprising limaprost and β-cyclodextrin, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass based on 100% by mass of the total tablet content.

2. The tablet according to claim 1, wherein the content of β-cyclodextrin is from 50% by mass to 95% by mass based on 100% by mass of the total tablet content.

3. The tablet according to claim 1 or 2, which may further comprise 0.0165% by mass to 2.5% by mass of glucans.

4. The tablet according to any one of claims 1 to 3 comprising limaprost as limaprost alfadex, wherein the tablet at least comprises a mixture comprising (1) lyophilized composition comprising limaprost alfadex and (2) β-cyclodextrin.

5. The tablet according to claim 4 which is manufactured through a step of admixing the β-cyclodextrin in (2) without a solvent.

6. The tablet according to claim 5, which further comprises β-cyclodextrin in the lyophilized composition.

7. The tablet according to claim 6, wherein the content of β-cyclodextrin in the lyophilized composition is from 0.1% by mass to 1% by mass based on 100% by mass of the total tablet content.

8. The tablet according to any one of claims 4 to 7, which further comprises glucans in the lyophilized composition.

9. The tablet according to claim 8, comprising limaprost alfadex and glucans with the ratio of 1:0.1 to 15.

10. The tablet according to claim 8, comprising limaprost alfadex and glucans with the ratio of 1:0.1 to 6.

11. A tablet comprising limaprost alfadex, β-cyclodextrin and glucans, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass and the content of glucans is from 0.0165% by mass to 2.5% by mass based on 100% by mass of the total tablet content.

12. A tablet comprising a mixture of (1) lyophilized composition comprising limaprost alfadex, β-cyclodextrin and glucans and (2) β-cyclodextrin, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass and the content of glucans is from 0.0165% by mass to 1.0% by mass based on 100% by mass of the total tablet content.

13. The tablet according to any one of claims 1 to 12 which does not comprise substantially 17S,20-dimethyl-trans-Δ^2-PGA_1 in the tablet or comprises 5% or less of 17S,20-dimethyl-trans-Δ^2-PGA_1 based on 100% of the total tablet content after preservation at 30°C, relative humidity of 75% for a month.

Claims

1. A tablet comprising a mixture of (1) limaprost alfadex and (2) β-cyclodextrin, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass based on 100% by mass of the total tablet content.

2. The tablet according to claim 1, wherein the content of β-cyclodextrin is from 50% by mass to 95% by mass based on 100% by mass of the total tablet content.

3. The tablet according to claim 1 or 2, which may further comprise 0.0165% by mass to 2.5% by mass of glucans.

4. The tablet according to any one of claims 1 to 3, wherein the tablet at least comprises a mixture comprising (1) lyophilized composition comprising limaprost alfadex and (2) β-cyclodextrin.

5. The tablet according to claim 4 which is manufactured through a step of admixing the β-cyclodextrin in (2) without a solvent.

6. The tablet according to claim 5, which further comprises β-cyclodextrin in the lyophilized composition.

7. The tablet according to claim 6, wherein the content of β-cyclodextrin in the lyophilized composition is from 0.1% by mass to 1% by mass based on 100% by mass of the total tablet content.

8. The tablet according to any one of claims 4 to 7, which further comprises glucans in the lyophilized composition.

9. The tablet according to claim 8, comprising limaprost alfadex and glucans with the ratio of 1:0.1 to 15.

10. The tablet according to claim 8, comprising limaprost alfadex and glucans with the ratio of 1:0.1 to 6.

11. A tablet comprising limaprost alfadex, β-cyclodextrin and glucans, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass and the content of glucans is from 0.0165% by mass to 2.5% by mass based on 100% by mass of the total tablet content.

12. A tablet comprising a mixture of (1) lyophilized composition comprising limaprost alfadex, β-cyclodextrin and glucans and (2) β-cyclodextrin, wherein the content of β-cyclodextrin is from 30% by mass to 99% by mass and the content of glucans is from 0.0165% by mass to 1.0% by mass based on 100% by mass of the total tablet content.

13. The tablet according to any one of claims 1 to 12 which does not comprise substantially 17S,20-dimethyl-trans-Δ^2-PGA_1 in the tablet or comprises less than 5% of 17S,20-dimethyl-trans-Δ^2-PGA_1 based on 100% of the total tablet content after preservation at 30°C, relative humidity of 75% for a month.